Genetic Technologies Limited

ASX:GTG ISIN:AU000000GTG7

Genetic Technologies was an early pioneer in recognizing important new applications for "non-coding" DNA (DeoxyriboNucleic Acid). The Company has since been granted patents in 24 countries around the world, securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all multicellular species. Its three-pronged business strategy includes: 1) the global commercialization of its patents through an active licensing program; 2) the expansion of its dominant commercial genetic testing business in Australia; and, 3) the commercialization of its various research and development projects aimed at generating further intellectual property of global commercial significance. 
 
     

查看其它語言版本

新聞

1月7日澳洲股市:對鐵礦石價格樂觀

🕔1/7/2010 9:30:30 AM 12968

根據澳洲統計局的數據,澳洲建築審批數在11月增長到13,724 幢,經季節因素調整後,較10月份向上修正後的數字12,962幢增加了5.9%。儘管有澳儲行升息和逐步撤消政府首次購房者補貼的舉措,此結果仍好於市場預期。

閱讀全文
###

45,897 公司背景瀏覽

  • 本頁瀏覽人次: (過去7日: 12) (過去30日: 53) (自發布以來: 7476) 

公司詳細

    傳真
  • (03) 9417 2987 
  • 主要部門
  • 醫療-製藥 
  • 支柱產業
  • 生物科技 
  • 主頁
  • www.gtg.com.au/

更多新聞紀錄

  • 2024/03/26: GTG Secures Short Term Loan Facility with Radium Capital*
  • 2024/03/25: Appointment of CFO & Company Secretary*
  • 2024/03/22: GTG to develop Worlds Most Advanced Comprehensive Risk Test*
  • 2024/03/20: Results of Extraordinary General Meeting*
  • 2024/03/07: Appendix 3Y - Change of Director's Interest Notice*
  • 2024/02/28: GTG to launch U.S. Customer Digital Media Sales Campaign*
  • 2024/02/23: Appendix 4D & Half-year Financial Report - 31 December 2023*
  • 2024/02/20: Notice of Extraordinary General Meeting & Sample Proxy Form*
*refer to company website